Minnesota
For Minnesota, generic/biosimilar trigger is 50% over the previous 12 months; statute is S.F. 2995, verified against its source on 2026-09-29.
- State
- Minnesota our reading
- Generic/biosimilar trigger
- 50% over the previous 12 months verified
- Statute
- S.F. 2995 verified
Values marked our reading are our classification of what the source says — the source does not print them in those words. The quote below is the evidence for each one; judge it yourself.
What the source says
Minnesota: S.F. 2995 amends the state’s Prescription Drug Price Transparency Act to include some technical fixes and clarifications, such as explicitly including “biosimilars” along with generic drugs in the provision that triggers reporting when there is a WAC increase of at least 50% over the previous 12 months.
— goodwinlaw.com, retrieved 2026-08-14
Source
- goodwinlaw.comhttps://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws